Why
Liposomal
Amphotericin
B
Liposomal
Amphotericin
B
Why Liposomal Amphotericin B
I Am… Liposomal Amphotericin B: Ready to fight Ahmad's
life-threatening mucormycosis infection
life-threatening mucormycosis infection
Ahmad's uncontrolled diabetes was a major risk factor for
mucormycosis, particularly for ROC presentations.7 ROC
mucormycosis is a rapidly progressive disease, associated
with high mortality rates of up to 60%, despite treatment.
Many survivors are also left with life-long effects, such as
permanent loss of vision.8
mucormycosis, particularly for ROC presentations.7 ROC
mucormycosis is a rapidly progressive disease, associated
with high mortality rates of up to 60%, despite treatment.
Many survivors are also left with life-long effects, such as
permanent loss of vision.8
*The clinical relevance of these animal studies in humans is unknown.16
**Please refer to the Liposomal Amphotericin B Summary of Product Characteristics for detailed information on safety profile.
DAY 0(continued)
Liposomal Amphotericin B initiated
DAY 2
Transfer to specialist ICU
Fungicidal effect on Mucorales9–11
Liposomal Amphotericin B has greater fungicidal activity
against Mucorales vs. echinocandins (shown to have
limited to no activity against Mucor spp. in vitro) and
some azoles9,10 (mostly fungistatic9,11).
against Mucorales vs. echinocandins (shown to have
limited to no activity against Mucor spp. in vitro) and
some azoles9,10 (mostly fungistatic9,11).
A well-established tolerability and
safety profile6**
safety profile6**
Very common adverse events associated with Liposomal
Amphotericin B treatment include rigors, pyrexia,
hypokalaemia, nausea and vomiting.6
Amphotericin B treatment include rigors, pyrexia,
hypokalaemia, nausea and vomiting.6
Prompt treatment may help to
reduce mortality12
reduce mortality12
Delayed initiation of amphotericin B, the active ingredient in
Liposomal Amphotericin B, was identified as an
independent predicator of poor outcome in patients with
mucormycosis (OR, 8.1; 95% CI, 1.7–38.2; p=0.008).
Mortality rate reduced with early treatment vs. delaying
treatment in patients with mucormycosis at Week 4
(35.1% vs. 66.6%; p=0.006) and Week 12 (48.6% vs.
82.9%; p=0.03).*12
Liposomal Amphotericin B, was identified as an
independent predicator of poor outcome in patients with
mucormycosis (OR, 8.1; 95% CI, 1.7–38.2; p=0.008).
Mortality rate reduced with early treatment vs. delaying
treatment in patients with mucormycosis at Week 4
(35.1% vs. 66.6%; p=0.006) and Week 12 (48.6% vs.
82.9%; p=0.03).*12
View footnotes to proceed
